Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer

PD1 blockade to reinvigorate T cells has become part of standard of care for patients with NSCLC across disease stages. However, the majority of patients still do not respond. One potential mechanism of resistance is increased expression of other checkpoint inhibitory molecules on T cells leading to...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez, Marina, Kim, Soyeon, St. Jean, Naomi, O’Brien, Shaun, Lian, Lurong, Sun, Jing, Verona, Raluca I., Moon, Edmund
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833767/
https://www.ncbi.nlm.nih.gov/pubmed/33537176
http://dx.doi.org/10.1080/2162402X.2021.1873607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833767/
https://www.ncbi.nlm.nih.gov/pubmed/33537176
http://dx.doi.org/10.1080/2162402X.2021.1873607

Ejemplares similares